TAO Synergies Inc.
TAOX
Get informed when a big investor buys or sells
+ FollowMarket Cap$0
Close$
Share Statistics
| Market cap | - |
|---|---|
| Enterprise Value | - |
| Dividend Yield | $NaN (NaN%) |
| Earnings per Share | $- |
| Beta | - |
| Outstanding Shares | - |
Return
| Return on Equity | -124997.43% |
|---|---|
| Return on Assets | -93640.34% |
| Return on Invested Capital | -30215.26% |
Valuation & Multiples
| P/E Ratio | - |
|---|---|
| PEG | - |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | - |
| Enterprise Value to Net Income | 0 |
| Total Debt to Enterprise | - |
| Debt to Equity | 0 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 13, 2026
EPS Estimate
$-12.75
Average shareholder expectationRevenue Estimate
$88,626
Average shareholder expectationNext Earnings Call
Expected Date
December 2, 2026
EPS Estimate
$-12.75
Average shareholder expectationRevenue Estimate
$88,626
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Synaptogenix Inc
5 employees
CEO: Joshua N. Silverman TAO Synergies Inc. operates as a biopharmaceutical company currently in the clinical development stage. It is dedicated to advancing a bryostatin-1 therapeutic platform, specifically designed to combat Alzheimer's and various other neuro...